Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
Recruiting
N/A
Interventional Study
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
NAFLD - Non-Alcoholic Fatty Liver Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 110 (estimated)
- Sponsor
- ContextVision AB · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expensive or invasive. If successful, this ultrasound tool could become an easier and more accessible way …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Diseased subject:
* Adult patients (age 18 - 75 years)
* Consent to participate in the study
* Diagnosed or suspected MASLD from the hepatology clinic, OR
* High-risk population meeting the adult cardiometabolic criteria (defined as the presence of at least one of the following…
Contacts